LifeTech Scientific Corporation announced that its G-iliac™ Pro Iliac Artery Stent Graft System has obtained official registration approval from the China National Medical Products Administration (NMPA). The device, developed independently by the company, is indicated for the endovascular treatment of abdominal aortic aneurysms combined with iliac artery aneurysms or isolated common iliac artery aneurysms. This approval is expected to enhance clinical treatment options by enabling internal iliac artery reconstruction and improving existing protocols.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeTech Scientific Corporation published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260108-11985285), on January 08, 2026, and is solely responsible for the information contained therein.